Breast Cancer Prevention Drug Benefits Some But Not All Women At Risk

Breast Cancer Prevention Drug Benefits Some But Not All Women At Risk
shutterstock_224672638A team of researchers from the University of North Carolina recently found that Tamoxifen's benefits for breast cancer prevention can compensate its risks of adverse effects. However, not all women appear to benefit from the drug. Tamoxifen is a U.S. Food and Drug Administration approved drug for primary prevention of breast cancer. However, the drug is not usually recommended by clinicians as it increases the risks of adverse side effects. Due to the lack of evidence concerning risk-benefit profiles in women using chemoprevention, Dr. Hazel B. Nichols and colleagues sought to assess the characteristics associated with initiation and suspension of tamoxifen for primary prevention of breast cancer in women with first-degree relatives diagnosed with the disease. Those who participated in this research were part of The Sister Study, that enrolled 50,884 US and Puerto Rican women aged 35 to 74 years, between 2003 and 2009. The study entry criteria included women with no breast cancer but who had a sister with a breast cancer diagnosis. From the total cohort, the researchers identified 788 women that were taking tamoxifen and 3131 non-users controls. From these women, the researchers collected at baseline data on tamoxifen use, initiation and cessation of use and total time of drug intake. Data analysis performed with logistic regression revealed that 20% of women who used tamoxi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.